The Montreal clinical study COLCORONA will continue its third phase following encouraging preliminary results to cure people affected by COVID-19.
The Montreal Heart Institute (MHI) said in a statement on Sunday that the continued recruitment of out-of-hospital adult patients with COVID-19 has been authorized following a recommendation from the independent data monitoring committee following the second interim analysis of the study.
• Read also: COVID-19: Quebec has lost all of its progress
• Read also: COVID-19: steep fines for a party in Ontario
“We aim to complete the recruitment of patients in this large study during the next month and hope that colchicine will reduce the risk of complications related to COVID-19”, said Dr Jean-Claude Tardif, director of the Research Center of the ICM, professor of medicine at the University of Montreal and principal investigator of the COLCORONA study.
This initiative aims to find out whether colchicine can prevent the risk of serious complications from COVID-19. The Montreal Heart Institute clarified that “this is one of the few large-scale studies on COVID-19 in which out-patient patients can participate.”
Contactless, since being done at home for patients with the disease who do not need to be in hospital, this study is being carried out in Canada, the United States, Europe, South America and Africa. from South.
“With the dramatic increase in COVID-19 cases around the world, it becomes even more critical that we continue to seek treatments that can not only improve the situation of people hospitalized with serious complications, but also those with symptoms are less severe and can stay at home, ”said Dr Jean-Claude Tardif.
COLCORONA is funded by the Government of Quebec, the National Heart, Lung and Blood Institute of the United States and the Bill & Melinda Gates Foundation. The companies CGI, Dacima and Pharmascience are also working together.
Health professionals and patients affected by COVID-19 who would like to participate can inquire by calling 1 877 536-6837.